Vectura Group Stock Rating Reaffirmed by JPMorgan Chase & Co. (VEC)
Vectura Group (LON:VEC)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday, AnalystRatingsNetwork reports.
A number of other analysts have also recently weighed in on VEC. Analysts at N+1 Singer raised their price target on shares of Vectura Group from GBX 97 ($1.59) to GBX 110 ($1.81) in a research note to investors on Tuesday, January 14th. They now have a “sell” rating on the stock. Separately, analysts at FinnCap reiterated a “buy” rating on shares of Vectura Group in a research note to investors on Tuesday, January 14th. They now have a GBX 180 ($2.95) price target on the stock. Finally, analysts at Investec raised their price target on shares of Vectura Group from GBX 148 ($2.43) to GBX 170 ($2.79) in a research note to investors on Thursday, December 19th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of GBX 148.88 ($2.44).
Vectura Group (LON:VEC) traded down 0.31% during mid-day trading on Tuesday, hitting GBX 160.00. The stock had a trading volume of 527,848 shares. Vectura Group has a 52-week low of GBX 76.00 and a 52-week high of GBX 162.75. The stock’s 50-day moving average is GBX 138.0 and its 200-day moving average is GBX 112.1. The company’s market cap is £542.7 million.
Vectura Group plc (LON:VEC) is a developer of therapies principally for the treatment of respiratory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.